

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Poster presentation schedule

Tuesday, 3 December 2024

10:30 – 11:10

Drug Discovery	
P400	A promising MYLK4 Inhibitor for treating metastatic and drug-resistant colorectal cancer Adj A/Prof Min-Wu Chao, National Sun Yat-sen University
P402	Investigating the role of IA65 on thapsigargin-induced IL-6 gene expression via ORAI1 Jihye Han, The University of Queensland
P404	6-methyl(sulfinyl)hexyl isothiocyanate and glycyrrhetic acid enhances cytotoxicity in glioblastoma cells Hafsa Hersi, Bond University
P405	Casein kinase 1 delta is a key mediator of TGF-b1-induced pulmonary fibrosis Dr Meina Li, The University of Melbourne
P407	Nanoformulations for the Treatment of Biofilm-Associated Bacterial Infections Yuzhang Li, The University of Queensland
P409	A new paradigm for mRNA display selection by sequence space analysis Tommy Lu, The University of Sydney
P410	An in-vitro model to assess drug holiday regimes in resistance to dabrafenib Anika Nagarajan, The University of Queensland
P412	Anti-proliferative effects of HDAC8 PROTAC on HSCC cells via endoplasmic reticulum stress Phurinut Somachai, Faculty of Medicine Ramathibodi Hospital, Mahidol University
P416	Characterisation of the pro-atherosclerotic orphan G protein-coupled receptor, GPR146 Brendan Wilkins, UNSW Sydney
P418	Activation and allosteric modulation of the human GLP-1R by small-molecule ligands Dr Xin Zhang, Monash University
P420	The role of RGS2 in regulating GLP-1R function Yanxi Chang, Monash University
P422	Designing novel bivalent opioid peptides targeting kappa and nociceptin opioid receptors Muhaimin Habib, The University of Queensland
P529	Metformin-Mediated Improvement in Solubility, Stability, and Permeability of Nonsteroidal Anti-Inflammatory Drugs Prof Yong Lyu, Institute of Materia Medica, CAMS & PUMC/Chinese Pharmacological Society
P531	A Novel Cocrystal to Optimize the Solubility, Permeability and Bioavailability of Daidzein Prof Li Zhang, Institute of Materia Medica, Cams & Pumc/Chinese Pharmacological Society
P532	Exploring the role of cancer-associated fibroblasts on breast cancer cell death Dr Alice Hui Li Bong, The University of Queensland

Drug Disposition & Response	
P424	Targeted PAK1/PAK4 inhibition normalizes vasculature and boosts gemcitabine effectiveness in pancreatic cancer Arian Ansardamavandi, The University of Queensland
P426	Antenatal hypoxia or dexamethasone alter hepatic Cytochrome P450 activity in ovine offspring Millicent Bennett, The University of South Australia

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024
10:30 – 11:10

Drug Disposition & Response	
P428	CFTR modulator bidirectional transport through CLEFF4 monolayers, evidence of P-gp substrate affinity Dr Andrew Crowe, Curtin University
P430	LC-MSMS bioanalytical method for PBT2 and doxycycline quantification in mouse plasma microsamples Viet Tin Pham, The University of Queensland
P432	Mechanism-based modelling predicts antibiotic effect on Pseudomonas aeruginosa where PK/PD indices cannot Alice Terrill, Monash University
P434	Fetal rat ocular development after in utero exposure to elexacaftor-tezacaftor-ivacaftor Yimin Zhu, The University of Melbourne

Innovation & Industry	
P436	Navigating the Challenges of Cell and Gene Therapies- Nonclinical and Manufacturing Considerations Sharleen Menezes, Novotech
P438	Novel 96-Well Plate-Compatible Device for Studying GPCRs in a Fluid Flow System Renate Roeterink, The University of Melbourne

Neuropharmacology	
P440	CASK mediates oxidative stress-induced microglial cell death via p38 and Ca2+ influx Keith Jun Hao Cheong, National Taiwan University
P442	Cholinergic muscarinic type 4 receptor is the dominant driver of Xanomeline’s efficacy Dr Christopher (KH) Choy, Monash University
P444	Neural projection from intralimbic cortex to nucleus accumbens regulates methamphetamine reinstatement Prof Po-Wu Gean, National Cheng Kung University
P446	Mechanism underlying lactate release from astrocytes in brain ischemic tolerance Dr Yuri Hirayama, Chiba University
P448	Neuroprotective effect of astaxanthin nanoemulsion in middle cerebral artery occlusion stroke model Prof Igor Iezhitsa, IMU University, School of Medicine
P450	New fundamental therapeutics for Alzheimer's disease utilizing unused parts of medicinal plants Jae-Won Jung, University of Toyama
P452	CASK mediates UVA-induced Muller cell apoptosis via regulating AMPK and Ca2+ trafficking Dr Vladen Klochkov, Cardian Tien Hospital
P454	Deprescribing benzodiazepine receptor agonists in people living with dementia: a systematic review Aisling McEvoy, Monash university
P456	New myokine-mediated functional recovery in chronic phase of spinal cord injury Prof Chihiro Tohda, University of Toyama
P458	CASK involves in methylglyoxal-induced mitochondrial calcium overload and dysfunction in Müller cells Chuin Shung Yeoh, National Taiwan University

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024

10:30 – 11:10

Neuropharmacology

P460	Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder Dr Alene Yong, Monash University
P462	GABA-B receptor modulation in hPSCs-derived sensory neurons by baclofen and α-conotoxin Vc1.1 Dr Arsalan Yousuf, The University of Sydney
P464	Formononetin ameliorates chemotherapy-induced neurotoxicity in dorsal root ganglion neurons through Nrf-2/HO-1 pathway Yang-Chen Chang, Kaohsiung Medical University

Pharmacogenomics

P468	Self-pharmacogenomic testing increases pharmacy student confidence for future delivery of pharmacogenomic services Toni Michael, The University of Sydney
P470	Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services Tark Patel, The University of Sydney
P472	The Australian Public's Current Thoughts on Pharmacogenomics Richelle Breed, Queensland University of Technology
P474	Utilisation and associated factors of HLA-B*5701 testing among abacavir users in Australia Chin Hang You, The University of Sydney School of Pharmacy
P476	The Pharmacogenomics of Cisplatin Induced Ototoxicity David Harman, The University of South Australia

Pharmacy Practice

P478	Impact of medicines shortages in a developing country, Sri Lanka Nimmi Dilsha, Queensland University of Technology
P480	Prospective identification of medication harm in geriatric inpatients using a trigger tool Dr Nazanin Ghahreman-Falconer, The University of Queensland
P482	Electronic clinical pharmacy documents for quick and accurate clinical pharmacy performance measurement Huri Balikubiri, The University of South Australia
P484	Stakeholders' views on a virtual pharmacy discharge service for First Nations patients Bushra Haque, The University of Sydney
P486	Adverse events associated with cannabis-based product use in people living with cancer Dr Joanna Harnett, The University of Sydney
P488	Co-designing an intervention to optimise medicine information handover after discharge from hospital Dr Holly Foot, The University of South Australia
P490	Healthcare professional's attitudes towards new virtual transition of care stewardship pharmacist role Siniti Herath, The University of Sydney
P492	Multidisciplinary perspectives on hospital pharmacist roles in tertiary settings: a qualitative study Kyung Min Kirsten Lee, The University of South Australia
P494	Evaluating psychometric properties of medication-related quality indicators in RACHs: A systematic review Lakesha Sandamali Liyanage, The University of Canberra

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024
10:30 – 11:10

Pharmacy Practice	
P496	Medicine prices availability and affordability in 57 developing and middle-income countries Lachlan Oldfield, The University of Sydney
P498	Needs assessment of self-care facilitation by Indonesian community pharmacies to international travellers Antonius Pratama, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney
P500	Implementation of specialist-initiated Home Medicines Reviews for osteoporosis: patients' experiences of intervention Fatima Rezae, The University of Sydney
P502	Adverse drug event-related hospital admissions among Australian aged care residents Dr Mohammed Salahudeen, The University of Tasmania
P504	Paediatric off-label and unlicensed prescribing patterns in primary care: a systematic review Dr Julie Stevens, RMIT University
P506	Asthma Control and Management among Arabic-Speaking immigrants in Australia Dr Thilini Thrimawithana, RMIT University

Toxicology	
P508	Air pollution effects on genome stability: human biomonitoring and in vitro approach Dr Goran Gajski, Institute for Medical Research and Occupational Health
P510	Understanding the pharmacokinetics of enteric coated sodium valproate in overdose Prof Andrew Rowland, Flinders University
P512	Molecular mechanism of malignant change by Benzopyrene-induced cellular senescence Natsuko Kitamoto, Osaka University
P514	CASK mediates docetaxel- and oxidative stress-induced prostate cancer cell death Prof Wan-wan Lin, National Taiwan University

Urogenital and Gastrointestinal	
P516	CXCL5 inhibition improved renal tubular epithelial cells injury of diabetic kidney disease Ching Chen, National Yang Ming Chiao Tung University
P518	Considerations of the expanded guanylate cyclase family in gastrointestinal health Dr Helen Irving, La Trobe University
P520	Cytotoxicity of Doxazosin in Bladder Cancer Cells and Effects on Bladder Function Liam O'Callaghan, Bond University
P522	Could darifenacin side effects include non-muscarinic interactions in the bladder? Vineesha Veer, Bond University
P524	Polymerization level of dietary fructans differentially affect the intestinal microbiota interactions Qin Yuan, University of Macau
P526	Effects of acute hypoxia and pre-conditioning on contractility of isolated porcine urethra Prof Donna Sellers, Bond University
P528	The effect of chemical hypoxia on urothelial mediator release Elouise Tye, Bond University

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024
13:15 – 14:10

Drug Discovery	
P401	High-throughput pharmacokinetic predictions in early drug development Dr Jeremy Jones, Simulations Plus
P403	ERRy loss promotes neuroendocrine differentiation in PTEN-deficient prostate cancer Dr Ting Li, University of Macau
P406	Dendritic cell extracellular vesicle mimetics show potential for activating CD4+ T cells Eleanor Mills, Monash University
P408	Distinct fingerprint of formyl peptide receptor 2 agonists: the secret to bias? Cheng Peng, Monash University
P411	Tomentosenol A, isolated from bee propolis, inhibits TGF-β1/SMAD3 signalling in human fibroblasts Lisa Randall, The University of the Sunshine Coast
P413	Utilising bioluminescence resonance energy transfer to elucidate novel pharmacology of AT1-LOX-1 heteromer Julyan Tan, The University of Western Australia
P415	Discovering a Novel DYRK1A Inhibitor and Its Impact on Alzheimer’s disease Dr Huanglu Tu, Taipei Medical University
P417	Pharmacological evaluation of beta-endorphin analogues: opioid-based bivalent peptides targeting multiple opioid receptors Yifan Wang, The University of Queensland
P419	Identification of anti-inflammatory ligands of GPCRs from natural products Prof Richard Ye, The Chinese University Of Hong Kong - Shenzhen
P421	Targeting peripheral mu and delta receptors with bivalent opioid peptides Junkai Zhang, The University of Queensland
P423	Influence of medium composition and dimensionality of culture on tumour cell characteristics Xiaodan Zhang, The University of Melbourne
P263	The role of RGS2 in ligand-mediated signalling of PAC1R splice isoforms Miaomiao Li, Monash University
P530	Improving the hygroscopicity and bioavailability of ligustrazine using cocrystallization technology Dr Xie Yifei, Institute of Materia Medica, CAMS & PUMC/Chinese Pharmacological Society

Drug Disposition & Response	
P425	The effects of different resistance mechanisms on Pseudomonas aeruginosa response to meropenem Dominika Fuhs, Monash University
P427	Effect of oxycodone, polypharmacy, deprescribing on pain, function, cognition and molecular changes Dr John Mach, Kolling Institute
P429	Effect of allyl isothiocyanate in the paediatric ALL cell line REH Dr Suong Ngo, The University of Adelaide
P431	Synergistic combination therapy of aztreonam and ciprofloxacin against resistant Pseudomonas aeruginosa strains Charlotte Picton, Monash University
P433	Extracellular vesicles are a broadly applicable liquid biopsy to characterize medicines exposure Prof Andrew Rowland, Flinders University

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024

13:15 – 14:10

Innovation & Industry	
P435	Medicine policies and innovation: a comparison of Australia, Malaysia and China Dr Orin Chisholm, University of Sydney
P437	Machine Learning tool for Pharmacokinetic and Pharmacodynamic model prediction using RsNLME-Pydarwin Dr Chandramouli Radhakrishnan, Certara
P439	Impact of medicines demand forecast accuracy on medicines shortages in Sri Lanka Nimmi Dilsha, Queensland University of Technology

Neuropharmacology	
P441	Investigating benzodiazepine and vinpocetine sensitivity of GABAA variants in patients with epilepsy Taegan Charles, The University of Sydney
P443	Unravelling the mechanisms for internalisation and subcellular trafficking of the M4 receptor Yingshan Dong, Monash Institute of Pharmaceutical Science
P445	Understanding the interplay of STING and TOLLIP in driving secondary injury post-TBI Amelia Fryer, The University of Melbourne
P447	Dissecting the role of differential phosphorylation in mGlu5 signalling and regulation Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences
P449	Efficacy and Safety of Immunotherapies for Alzheimer's Disease: A Network Meta-Analysis Prof Igor Iezhitsa, IMU University, School of Medicine
P451	Testosterone signaling in microglia: its roles for sex differences in Alzheimer's Disease Prof Takashi Kanematsu, Kyushu University
P453	Structural Insights into Positive Allosteric Modulation at the M4 muscarinic acetylcholine receptor Michaela Kaoullas, Monash University
P455	Exploring sex-differences of metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators (NAMs) Jackson Kos, Monash University
P457	Evolution of 5-HT3 receptors in animals and their moonlighting roles in mitochondria Dr Santosh RamaBhadra Rao Tata, La Trobe University
P459	Diosgenin improves cognition in Alzheimer's disease model mice and humans Prof Chihiro Tohda, University of Toyama
P461	Promoting microglial and macrophage uptake of amyloid-β proteins using diabodies Dr Emma Van Der Westhuizen, St Vincent's Institute of Medical Research
P463	Dexmedetomidine retracts hippocampal astrocyte processes in vivo Shu Watanuki, Hokkaido University
P465	Vagus nerve stimulation ameliorates cortical spreading depression via activation of locus coeruleus Tzu-Chiao Wei, National Yang Ming Chiao Tung University/Institute of Pharmacology

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024

13:15 – 14:10

Pharmacogenomics

P467	Economic impact of increasing TPMT testing rates prior to thiopurine drug therapy Bella Ianni, The University of Sydney
P469	Elucidating Psychiatric Disorder, Antipsychotic, and Metabolic Syndrome Genetic Connection in GWAS Rory Shepherd, The University of South Australia
P471	Exploring the nicotine metabolite ratio among people who smoke or vape Min-Tz Weng, The University of Queensland
P473	Utilisation and associated factors of TPMT testing among thiopurine users in Australia Chin Hang You, The University of Sydney School of Pharmacy
P475	Drug interactions, adverse effects and pharmacogenomic implications of polypharmacy in cystic fibrosis A/Prof Vincent Chan, RMIT University

Pharmacy Practice

P477	The development of an aggregated medication review taxonomy: a systematic scoping review Timothy Yeo, The University of Sydney
P479	Evaluation of electronic partnered pharmacist medication prescribing: a multi-centre matched cohort study Hana Amer, University of South Australia
P481	Pharmacist-led transition of care services in patients with cardiovascular disease Dr Nazanin Ghahreman-Falconer, The University of Queensland
P483	Feasibility and Acceptability of a Nurse-Pharmacist Post-Discharge Telehealth Heart Failure Service Joshua Bennetts, The University of Newcastle
P485	Pharmacists' potential roles within a youth mental health service: a qualitative exploration Sanam Fathabadi, The University of Sydney
P487	Are we ignoring a burden of preventable harm - drug-herb interaction risks? Dr Jocelin Chan, The University of Sydney
P489	Getting rid of FRIDs: Addressing the use of fall-risk-increasing drugs in aged-care Catherine Laird, The University of Technology Sydney
P491	Usage trends in Pharmaceutical Benefits Scheme cancer drugs in Australia: an analysis Jasmine Lee, The University of Sydney
P493	Implementation of a proposed algorithm to de-labelling penicillin allergy in community pharmacy Dr Angelina Lim, Monash University
P495	Effectiveness of interventions to increase safe and appropriate medicine disposal: systematic review Amy Ma, The University of Sydney
P497	Pharmacists are responsible for patient outcomes when dispensing opioids William Olsen, The University of Queensland
P499	Impact of futile medications on performance capacity in palliative care: Systematic review Jenna Powell, The University of Sydney
P501	Influence of beliefs and health literacy on medication-related outcomes in older adults Eman Rafhi, RMIT University
P503	Ward pharmacists' awareness, perceptions and experiences of PPMC provided in the ED Dr Mohammed Salahudeen, The University of Tasmania
P505	Exploring Sick Day Medication Guidance via Medication Management Reviews Mimi Truong, The University of Sydney

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #asceptapfpapsa

Supported by:



Tuesday, 3 December 2024
13:15 – 14:10

Toxicology	
P507	Effect of thiamine supplementation on hepatic GIP modification in obese diabetic rats Dr Yuka Kohda, Osaka Medical and Pharmaceutical University
P509	UVA induces glycolytic reprogramming by regulating acid extruders in A375 melanoma cells Pin-Chen Lin, Department of Pharmacology, National Defense Medical Center
P511	Cytotoxicity assessment employing environmentally relevant micro- and nanoplastics libraries Dr Yuya Haga, Osaka University
P513	Effects of heavy metals on interleukin-8 release from prostate stromal WPMY-1 cells Chadchan Supsamarnwong, Faculty of Medicine Ramathibodi Hospital, Mahidol University
P515	Oxyresveratrol and resveratrol reduce lead-induced IL-6 and IL-8 secretion from human astrocytes Putin Nudaeng, Faculty of Medicine Ramathibodi Hospital, Mahidol University

Urogenital and Gastrointestinal	
P517	Diosgenin attenuated ischemia-reperfusion injury-induced AKI and AKI-to-CKD transition Tien Yun Lan, National Yang Ming Chiao Tung University
P519	Pharmacological investigation of 5-HT effects on the isolated porcine urethra Dr Iris Lim, Bond University
P521	Uropathogenic Escherichia coli causes significant urothelial damage in ex vivo porcine bladders A/Prof Lu Liu, UNSW Sydney
P523	Depressed porcine ureter contractility with acute hypoxia is not alleviated by pre-conditioning Prof Donna Sellers, Bond University
P525	Targeting pain: A novel adjunct treatment to relieve BCG-immunotherapy induced side effects Georgia Bourlotos, Flinders Health and Medical Research Institute
P527	Impact of structural difference in fructans from polygonatum cyrtoneura on anti-inflammatory activity Qin Yuan, University of Macau